일반의약품 : 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Over the Counter Drugs Market was valued at USD 187.2 billion in 2025 and is estimated to grow at a CAGR of 6.1% to reach USD 333.2 billion by 2035.

The growth trajectory is shaped by a clear shift toward self-directed healthcare, where consumers increasingly rely on non-prescription medications to address routine health concerns. Rising healthcare costs and broader access to medical information have encouraged individuals to manage minor conditions without clinical intervention. Demand has also strengthened due to heightened awareness around preventive care and general wellness, alongside demographic shifts that expand the consumer base. The market continues to benefit from the growing availability of products across digital and retail platforms, improving accessibility and convenience for end users. In addition, favorable regulatory support enabling prescription-to-non-prescription transitions has widened product availability, while competitive pricing strategies and generic alternatives have improved affordability. Over the counter drugs, regulated for safety and effectiveness, remain a core component of self-care practices, supporting consistent market growth.

The cold and cough remedies segment accounted for USD 45.7 billion in 2025, maintaining a leading position within the overall market. Demand is driven by the frequent occurrence of respiratory-related conditions that require quick and accessible symptom management. Consumers continue to prefer readily available non-prescription solutions that provide immediate relief, contributing to sustained segment growth.

The tablets segment generated USD 119.8 billion in 2025 and is projected to reach USD 218.8 billion by 2035, reinforcing its dominance in the dosage form category. Tablets are widely preferred due to their convenience, precise dosage, and ease of storage, making them a practical choice for self-administered treatment. Continuous product introductions and regulatory approvals have further strengthened their availability and adoption across various therapeutic categories.

North America Over the Counter Drugs Market held a share of 31.9% in 2025, reflecting its strong position in the global landscape. The region benefits from well-established healthcare systems, high awareness of self-care practices, and widespread access to a diverse range of non-prescription medications. The increasing prevalence of chronic and lifestyle-related conditions continues to support consistent demand, while advanced retail and digital distribution channels enhance product reach and consumer engagement.

Key companies operating in the Over The Counter Drugs Market include Abbott Laboratories, Bayer, Cipla, Haleon, Kenvue, Reckitt, Sanofi, Perrigo Company, Procter & Gamble Company, Teva Pharmaceutical, Dr. Reddy's Laboratories, Sun Pharma, Glenmark Pharmaceuticals, Himalaya Wellness Company, Piramal Pharma, Alkem Laboratories, Taisho Pharmaceutical, Stada Arzneimittel, and Alinamin Pharmaceutical (The Blackstone Group). Companies in the Over the Counter Drugs Market are strengthening their competitive position through continuous product innovation, portfolio expansion, and strategic regulatory approvals. They are investing in research and development to introduce advanced formulations that enhance efficacy, safety, and convenience for consumers. Expanding digital presence through e-commerce platforms and pharmacy applications is improving product accessibility and customer engagement. Firms are also leveraging branding, targeted marketing, and consumer education initiatives to build trust and increase awareness. Strategic partnerships, mergers, and acquisitions enable companies to broaden their geographic footprint and distribution networks. Additionally, a strong focus on cost optimization, private-label offerings, and sustainable packaging solutions is helping organizations align with evolving consumer preferences and regulatory expectations.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Business trends
  • 2.2.2 Regional trends
  • 2.2.3 Drug category trends
  • 2.2.4 Formulation type trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing consumer awareness for self-medication and disease management
    • 3.2.1.2 High cost of prescription drugs leading to shift towards OTC drugs
    • 3.2.1.3 Favorable regulatory support for OTC drug approvals
    • 3.2.1.4 Expanding product accessibility
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Concerns regarding misuse or drug abuse
    • 3.2.2.2 Potential side effects and drug interactions
  • 3.2.3 Market opportunities
    • 3.2.3.1 Emerging markets expansion
    • 3.2.3.2 Increasing penetration and adoption of e-pharmacies and online platforms
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology/innovation landscape
  • 3.5.1 Novel drug delivery systems for OTC products
  • 3.5.2 Smart packaging & patient adherence technologies
• 3.6 Prescription to nonprescription switch list
• 3.7 Patent landscape (Driven by Primary Research)
• 3.8 Self-care & consumer health behavior trends
• 3.9 Future market trends (Driven by Primary Research)
• 3.10 Impact of AI and generative AI on the market
• 3.11 Porter’s analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Category, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Cold and cough remedies
• 5.3 Vitamins and supplements
• 5.4 Digestive and intestinal remedies
• 5.5 Skin treatment
• 5.6 Analgesics
• 5.7 Sleeping aids
• 5.8 Other drug categories

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Liquids
• 6.4 Ointments
• 6.5 Sprays

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Online channels
• 7.3 Offline channels
  • 7.3.1 Hospital pharmacies
  • 7.3.2 Retail pharmacies
  • 7.3.3 Other offline channels

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Alinamin Pharmaceutical (The Blackstone Group)
• 9.3 Alkem Laboratories
• 9.4 Bayer
• 9.5 Cipla
• 9.6 Dr. Reddy’s Laboratories
• 9.7 Glenmark Pharmaceuticals
• 9.8 Haleon
• 9.9 Himalaya Wellness Company
• 9.10 Kenvue
• 9.11 Perrigo Company
• 9.12 Piramal Pharma
• 9.13 Procter & Gamble Company
• 9.14 Reckitt
• 9.15 Sanofi
• 9.16 Stada Arzneimittel
• 9.17 Sun Pharma
• 9.18 Taisho Pharmaceutical
• 9.19 Teva Pharmaceutical